Gilead made an excellent move acquiring Kite Pharma because a drug that Kite developed has just been approved by the U.S. FDA. It was on Wednesday that the FDA gave the green light to a new therapy to treat a type of lymphoma called Yescarta. The drug will be priced at $373,000 for one administration … Continue reading “Gilead Shares Move Higher After FDA Approves its Cancer Drug”
